Trial Profile

A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Tagraxofusp (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Stemline Therapeutics

13 Jan 2022 Status changed from completed to discontinued.
14 Dec 2021 Early results of translational correlative studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort presented at the 63rd American Society of Hematology Annual Meeting and Exposition
08 Dec 2020 Initial results of correlative science studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort (n=9), were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com